Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.33 |
| ▸ | CA1 | P00915 | 5/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13128204 | 0.88 | — | — | |
| SCHEMBL13128203 | 0.81 | TDP1 (0.48) | CA12CA1CA14CA2CA7 | |
| SCHEMBL10099084 | 0.80 | CA12 (0.46) | CA12CA1CA14CA2CA7 | |
| SCHEMBL8208639 | 0.80 | CA12 (0.38) | CA12CA1CA14CA2CA7 | |
| SCHEMBL2419235 | 0.80 | CA12 (0.38) | CA12CA1CA14CA2CA7 | |
| SCHEMBL13128207 | 0.79 | CA12 (0.37) | CA12CA1CA14CA2CA7 | |
| SCHEMBL2807497 | 0.79 | CYP4F2 (0.30) | CYP4F2CYP4A11 | |
| SCHEMBL25736271 | 0.79 | TDP1 (0.43) | CA12CA1CA14CA2CA7 | |
| SCHEMBL13128206 | 0.78 | CA12 (0.39) | CA12CA1CA14CA2CA7 | |
| SCHEMBL6872276 | 0.77 | CA12 (0.37) | CA12CA1CA14CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | CA12 2033/4885CA1 3665/4885CA14 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.